CA
NZ
UK
AU
IND
US
● Neumora Therapeutics develops therapies for central-nervous-system and neuropsychiatric conditions, an area of large unmet need where new mechanisms have historically been difficult to validate.
Nemaura Medical, Inc (OTC:NMRD) once traded on the Nasdaq as a promising developer of needle-free glucose monitoring, but today its shares sit in the over-the-counter market at a fraction of a cent, effectively flat in the last closing session. For a name built around …
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has quietly built one of the more tangible commercial stories among micro-cap neurotech names, turning a specialized electrode technology into cleared, revenue-generating products. A slight pullback in the shares is what flagged the ticker, but the durable narrative …
Motus GI Holdings (OTC:MOTS) drew notice at the close for a 100% single-session gain, but the arithmetic behind that number is less dramatic than the headline figure suggests. Shares moved from $0.0001 to $0.0002, a rise of exactly one hundredth of a cent, on …
For a rare-disease developer that spent years building toward a pivotal readout, 2026 has been a story of expectations meeting hard data. Mereo BioPharma Group plc (NASDAQ:MREO) heads into the autumn under pressure, its shares soft as investors digest a Phase 3 program that …
● The roughly 10% single-session decline is the immediate hook, but no single, clearly identifiable public catalyst explains that specific move.
● That restraint is appropriate: while the September 9 disclosure is the company's most recent development, a small daily move cannot be definitively attributed to any single event.
● MaxCyte has built aBusinessmost investors never see directly: it supplies the cell-engineering technology that helps biotech companies develop cell and gene therapies.
Myriad Genetics has become one of 2026's more closely tracked diagnostics turnaround stories, and not for flattering reasons. After a steep share-price decline and a wave of analyst downgrades, the molecular-diagnostics veteran enters the autumn trading near multi-year lows, with investors focused squarely on …
● Based in Danbury, Connecticut, MannKind develops treatments for endocrine and orphan lung diseases built on its proprietary Technosphere dry-powder inhalation platform.
Please wait processing your request...